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The favorable results reported by Schmidt (1) stimulated our interest in
treating lupus erythematosus with 2% colloidal gold sulphide [aurol-sulfide-
(Hille)] and nicotinic acid.
CASE MATERIAL
Fifty-three adults with chronic discoid lupus erythematosus and one with
subacute lupus erythematosus disseminatus were treated. No selection of case
material was made other than to exclude patients with renal or hepatic disease.
Considerable variation in the duration and severity of the disease was exhibited.
In one case the disease had been present only three weeks whereas in another
the duration was as long as 36 years. In the majority of the chronic cases, 32/53,
the disease had been present longer than three years, in 14/53 approximately
six months to two years, and in 7/53 less than six months. Some patients (15/53)
presented one or two typical discoid plaques on the malar area or the temple,
whereas others (25/53) presented a number of edematous or discoid plaques
distributed over the face and scalp, and still others (13/53) had lesions distributed
over the face, chest, hack and upper extremities. A few patients had had little
or no previous treatment, some had had bismuth and/or aurol therapy and still
others had run the entire gamut of therapeutic procedures: bismuth, chryso-
therapy, oxophenarsine hydrochloride (Mapharsen—Parke, Davis), chaulmoogra
derivatives (Chaumesterol—Winthrop, Steam), cryotherapy and the Hollander
treatment.
METHOD OF TREATMENT
Aurol-Sulfide (Rule) was administered in accordance with the schedule recommended
by Schmidt. The initial dose of 2 cc. was increased by 1 cc. on subsequent injections, until
a maximum of 4 or 5 cc. was reached. The drug was injected intravenously ["intramuscular
and oral routes may be used" (1)] at weekly intervals and each injection was preceded by
the ingestion of 100 mg. of nicotinic acid. The venipuncture was made approximately fif-
teen minutes after the ingestion of this vasodilator, at the height of the flush reaction.
Nicotinic acid, 50 or 100 mgs., was prescribed to be taken three times a day after meals
throughout the course of treatment, "to increase the flow of blood to the skin by overcoming
vasospasm" (1). The patients included in this report had a minimum of 19 cc. (course of 5
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injections), an average of 55 cc. (11 or 12 injections) and a maximum of 129 cc. (a course of
27 injections).
Urinanalyses and complete blood counts were done at biweekly intervals in anticipation
of possible renal damage and bone marrow depression. Laboratory studies for potential
hepatic damage were not included because of the many different tests required to estimate
hepatic function.
RESULTS
Only those cases have been included in the evaluation of the therapeutic
response in which a minimum of 19 cc. (course of 5 injections) was administered.
Treatment had to be discontinued after the first few injections in seven cases
because of toxic reactions which will be described subsequently.
The results in 46 cases of chronic lupus erythematosus were as follows:
Healed 9/46 or 19+%
Striking improvement 5/46 or 34+%
Moderate improvement 11/46 or 23+%
Some improvement 3/46 or 6+%
Unimproved 8/46 or 17+%
Relapse 0/46
The cases that healed received a minimum total dose of 20 cc., an average total
dose of 50 cc. andL a maximum total dose of 94 cc. Improvement was noted in
one case after 9 cc. (three injections) in some after 24 cc. (five or six injections)
and in others not until 44 cc. (ten injections). Subjective as well as objective
improvement occurred in some cases. A few patients volunteered the information
that there was less itching and soreness. The cases that failed to respond or did
only moderately well received a minimum of 19 cc. (5 injections) an average of
53 cc. (12 injections) and a maximum of 91 cc. (20 injections).
An attempt was made to correlate the favorable response in some cases and
the lack of results in others with the duration of the disease and the severity
and extent (+—++ + )1 of cutaneous involvement. The cases were divided into
two groups: group A: those that healed or showed striking improvement and
group B: those that showed moderate, little or no improvement.
Group A Group 13
26/46 or 51+% 22/46 or 49+%
Duration
Less than 6 mo 4/24 or 16+% 1/22 or 4+%
6 mo. to 2 yrs 9/24 or 37+% 5/22 or 22+%
3 yrs 11/24 or 46+% 16/22 or 72+%
Involvement
+ 7/24or29+% 5/22 or 22+%
++ 12/24 or 50+% 2/22 or 54+%
+++ 5/24or20+% 5/22 or 22+%
One plus is used to designate one or two typical plaques, ++ a number of edematous
plaques distributed over the face and scalp, and +++ lesions distributed over the face,
chest, back and upper extremities.
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It appears that the cases in group B (little, moderate or no improvement)
were of greater chronicity but showed approximately the same degree of cu-
taneous involvement as the cases in group A (healed or striking improvement).
Our experience with colloidal gold sulphide therapy in subacute lupus ery-
thematosus disseminatus was limited to one case. There was no appreciable
change in the clinical picture, nor in the sedimentation rate after 91 cc. (20 in-
jections) had been administered.
TOXIC EFFECTS
Early Toxic Manifestations
In eight of the 53 cases, treatment had to be discontinued after the first few
injections because of an "immediate reaction" to the injection in four cases;
acute urticaria in one case; a moderate pancytopenia in one case; a rapid drop
in the leukocyte count in one case; and a leukopenia and an albuminuria in
one case). Among those who experienced untoward symptoms one complained
of a constricting pain in the arm radiating to the shoulder (venospasm?), after
each of the first three injections; two complained of a "grippe-like" feeling—
feverishness, chills and headache. A fourth complained of throbbing in the ears
lasting for ten minutes after the injection was completed. The patient who de-
veloped urticaria, had never had the condition prior to the administration of
colloidal gold and has remained well since. The eruption appeared within twenty-
four hours after the fourth injection and lasted two days.
The pancytopenia appeared after 13 cc. had been administered. The hemo-
gram read as follows: erythrocytes 3.4 million, hemoglobin 72%, leukocytes 2,900,
polymorphonuclear leukocytes 50% and lymphocytes 38%, platelets 70,000
per cu. mm., bleeding time of 6'5". In the second case the total leukocyte count
dropped to 2,900 cells per Cu. mm. after five cc. of aurol sulfide. The latter patient
gave a history of having developed "a bone marrow depression" a few years
previously after a course of oxophenarsine hydrochloride (Mapharsen—Parke,
Davis). In the third case, the leukopenia (3,600 white cells per Cu. mm.) and the
albuminuria along with a few red and white cells appeared after 13 cc.
Later Toxic Manifestations
A depression in the leukocyte count was the outstanding untoward effect. A leuko-
penia (less than 4,000 white blood corpuscles per cu. mm. of blood) was observed
in 19/45 or 42+% of cases. In 8/45 the white cells dropped to 3,500 cells per cu.
mm., in 9/45 the count fell below 3,500 per en. mm. The lowest figure in this
group was 2,000 cells per cu. mm. In 2/45 the depression of the leukocyte level
did not appear until six or eight weeks after treatment had been terminated.
Despite the high incidence of leukopenia, there was no instance of agranulocyto-
sis. A quantitative change in the differential count was also noted in a few cases:
a relative lymphocytosis (above 45%) in two cases and a relative monocytosis
(above 10%) from time to time in eight cases. The amount of colloidal gold re-
quired to produce a leukopenia varied considerably; as little as 5 cc. of aurol-
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suiphide was sufficient in one case, whereas in another, the leukopenia was not
apparent until fifty cc. had been administered. Treatment was discontinued in
4/19 of the cases. In each case there was a gradual return to normal values either
spontaneously or as a result of the parenteral administration of crude liver ex-
tract. Treatment was continued in 13/19 despite the leukopenia (the lowest
figure in this group was 2,800 white blood corpuscles per Cu. mm.). There was
no further drop in the leukocyte count. On the contrary, the number of white
cells began to increase and the total count gradually rose to previous levels.
The patient with subacute lupus erythematosus disseminatus also developed
a leukopenia of 3,300 cells per cu. mm. after 19 cc. were given. Treatment was
continued, and despite the administration of an additional 72 cc., the total white
cell count at the end of the course of therapy was 5,200 per cu. mm.
A faint trace of albumin was observed in four cases during the course of treat-
ment. In each case the albuminuria cleared despite continuation of therapy.
One patient complained of generalized pruritus after 55 cc. had been admin-
istered. This patient was entirely comfortable again within two weeks after
treatment was terminated. A focal reaction was noted in one case of discoid
lupus erythematosus after each injection. The lesion appeared redder and more
infiltrated a day or two after each injection. This heightened inflammation per-
sisted for a few days and then subsided again. It may be of interest to add that
this patient failed to improve.
The effectiveness of 2% colloidal gold sulphide combined with nicotinic acid
may be compared with Bistrimate [sodium bismuth triglycollanate (Smith)],
in view of our previous therapeutic assay of the latter (2). The results are as
follows:
Aural-Sulfide (Rule)
and nicotnie acid Bistrunale (Smith)
Healed 9/46 or 19+% 5/45 or 11+%
Improved 29/46 or 63+% 30/45 or 67+%
Unimproved 8/46 or 17+% 8/45 or 17+%
Relapse2 0/46 2/45 or 4%
The results with oral bismuth (Bistrimate) compare quite favorably with
parenteral aurol-sulfide therapy.
CONCLUSIONS
1) Aurol-Sulfide (Hille) combined with nicotinic acid was used in the treatment
of 53 cases of chronic discora lupus erythematosus and one case of subacutee lupus
erythematosus disseminatus. 19+% of the chronic cases healed and 34+%
showed striking improvement. The one case with the subacute form failed to
respond.
2) Hematologic manifestations of toxicity occurred in 40+ %and renal mani-
festation in 9+ %. Treatment was continued without apparent progressive dam-
age in presence of a mild leukopenia or albuminuria.
2 Relapse while under treatment.
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